Arrowhead Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arrowhead Pharmaceuticals, Inc.
Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.
Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.
With its first US study for a base-edited CAR-T therapy now back on track, Beam Therapeutics is gearing up to begin studies of its first in vivo candidate, BEAM-302, next year in AAT.
Elsewhere at the European Respiratory Society meeting, Bristol Myers Squibb will hope that its LPA1 antagonist can add a hit in progressive pulmonary fibrosis to the success it has already posted in the idiopathic form of the disease.
- Site Specific
- Drug Delivery
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Ablaris Therapeutics, Inc.
- Alvos Therapeutics, Inc. (formerly Mercator Therapeutics, Inc.)
- Arrowhead Research Corporation
- Calando Pharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.